Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
271.19
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
10 Health Care Stocks Whale Activity In Today's Session
October 05, 2023
Via
Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
September 29, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
September 12, 2023
Via
Benzinga
The Latest Analyst Ratings for Alnylam Pharmaceuticals
August 16, 2023
Via
Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
July 25, 2023
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
September 14, 2023
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.
Via
Benzinga
Exposures
Product Safety
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
September 14, 2023
Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug.
Via
Investor's Business Daily
Exposures
Product Safety
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
September 14, 2023
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.
Via
Benzinga
Exposures
Product Safety
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going
September 14, 2023
US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
September 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
September 13, 2023
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.
Via
InvestorPlace
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
September 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
September 11, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
September 08, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,
Via
Benzinga
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,
Via
Benzinga
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
September 07, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Exposures
COVID-19
Product Safety
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
September 05, 2023
Via
Benzinga
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
August 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
August 03, 2023
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
July 31, 2023
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key
Via
Benzinga
Lululemon Athletica To Rally Around 12%? Here Are 10 Other Analyst Forecasts For Tuesday
July 25, 2023
Needham raised the price target for F5, Inc. (NASDAQ: FFIV) from $175 to $180. Needham analyst Alex Henderson maintained a Buy rating. F5 shares jumped 11.2% to $167.00 in pre-market trading.
Via
Benzinga
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
July 24, 2023
Wall Street Journal
Via
Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
July 24, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to
Via
Benzinga
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
July 24, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.